|
Re: Revised target market, indications, market potential? ... and some numbers?
|
9
|
Resverlogix Corp.
|
Jun 13, 2020 05:15PM
|
|
Re: Resverlogix to Present at Upcoming Conferences
|
7
|
Resverlogix Corp.
|
Oct 13, 2021 02:39PM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
5
|
Resverlogix Corp.
|
Dec 02, 2019 04:42PM
|
|
Re: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019
|
5
|
Resverlogix Corp.
|
Dec 02, 2019 04:52PM
|
|
Re: Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
12
|
Resverlogix Corp.
|
Jan 27, 2021 08:11PM
|
|
Re: Resverlogix Invites Collaborations for use of Apabetalone in Trials and Studies to Combat the Spread of COVID-19 Based on New Research
|
2
|
Resverlogix Corp.
|
Mar 23, 2020 10:00AM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
6
|
Resverlogix Corp.
|
Mar 24, 2020 12:47PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
5
|
Resverlogix Corp.
|
Mar 26, 2020 06:08PM
|
|
Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication
|
2
|
Resverlogix Corp.
|
Mar 27, 2020 12:42PM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
8
|
Resverlogix Corp.
|
Sep 30, 2019 02:28PM
|
|
Re: Resverlogix Announces Topline Results in BETonMACE Phase 3 Epigenetics Trial
|
6
|
Resverlogix Corp.
|
Sep 30, 2019 02:36PM
|
|
Re: Resverlogix Announces Participation at the ACC/WCC Virtual Meeting
|
6
|
Resverlogix Corp.
|
Apr 01, 2020 06:18PM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
7
|
Resverlogix Corp.
|
Jun 13, 2023 07:24PM
|
|
Re: Resverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patients
|
4
|
Resverlogix Corp.
|
Jun 13, 2023 07:25PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call ... Bear
|
4
|
Resverlogix Corp.
|
Jun 08, 2020 10:47AM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
10
|
Resverlogix Corp.
|
Dec 22, 2020 04:02PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
4
|
Resverlogix Corp.
|
Dec 22, 2020 04:15PM
|
|
Re: Resverlogix Announces Apabetalone Prior to SARS-CoV-2 (COVID-19) Exposure Reduces Viral Infection – Confirms Plans for COVID-19 Clinical Trial
|
6
|
Resverlogix Corp.
|
Dec 22, 2020 05:16PM
|
|
Re: Regeneron drug saves lives in severe COVID-19, but it’s not for all
|
5
|
Resverlogix Corp.
|
Jun 16, 2021 02:39PM
|
|
Re: Recent findings point to BET protein and ACE2 inhibition as possible means to slow and reduce the impact of COVID-19....
|
2
|
Resverlogix Corp.
|
Mar 23, 2020 09:42AM
|
